secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0001193125-22-052216
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ikena Oncology appoints Francisco Olivera as acting Principal Accounting Officer (Feb 18, 2022)
--------------------------------------------------------------------------------

- Appointment made effective February 18, 2022, on an interim basis while a formal CFO search is conducted.
- Olivera currently serves as VP of Finance, joined the company in 2019, and has over a decade of biotech experience.
- He played a key role in the IPO, Series B financing, and acquisition of Amplify Medicines.
- No arrangements or understandings exist with any other person regarding the appointment; no related party transactions reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312522052216/0001193125-22-052216-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312522052216/d305562d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-052216

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer